Relmada Therapeutics pivots from psilocybin to cancer, neurological disorders
Green Market Report
Fri, Mar 28
Key Points
- Relmada Therapeutics is shifting its focus away from depression treatments and psychedelics.
- The company has acquired two new Phase 2 drug candidates.
- It is preparing to release topline Phase 2 data for NDV-01, a sustained-release intravesical formulation.
- Relmada Therapeutics is a clinical-stage biotechnology company.
Relmada Therapeutics (Nasdaq: RLMD) announced Thursday it was shifting away from its previous focus on depression treatments and psychedelics, after acquiring two new Phase 2 drug candidates.
The clinical-stage biotechnology company highlighted its upcoming release of topline Phase 2 data for NDV-01, which it describes as a sustained-release intravesical formulation for...
Please login to read all 379 words.
Discover